.Pharmacolibrary.Drugs.ATC.N.N02CD05 .Pharmacolibrary.Drugs.ATC.N.N02CD05| name: | Eptinezumab |
| ATC code: | N02CD05 | route: | intravenous |
| n-compartments | 2 |
Eptinezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), which is involved in migraine pathophysiology. It is used as a preventive treatment for migraine in adults and is approved for clinical use.
Pharmacokinetic parameters obtained from adult healthy volunteers and patients with migraine.
Li, XN, et al., & Larsen, F (2023). Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial. Clinical drug investigation 43(11) 873–881. DOI:10.1007/s40261-023-01315-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37917246
Hershey, AD, et al., & Rosen, M (2025). Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine. Headache None –. DOI:10.1111/head.14959 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40444655
Baker, B, et al., & Latham, J (2020). Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacology research & perspectives 8(2) e00567–None. DOI:10.1002/prp2.567 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32155317